Featured Research

from universities, journals, and other organizations

Compounds In Spinal Fluid Associated With Faster Decline Among Individuals With Mild Dementia

Date:
May 15, 2009
Source:
JAMA and Archives Journals
Summary:
Levels of biomarkers in the cerebrospinal fluid of individuals with very mild dementia may be associated with the rate at which their thinking, learning and memory skills decline, according to a new report.

Levels of biomarkers in the cerebrospinal fluid of individuals with very mild dementia may be associated with the rate at which their thinking, learning and memory skills decline, according to a new report.

Finding effective treatments for Alzheimer's disease will likely depend on early identification of patients, according to background information in the article. "Because there is a growing emphasis on enrolling individuals with less cognitive impairment into clinical trials of putative anti–Alzheimer's disease agents, methods are needed that will identify individuals with very mild dementia of the Alzheimer's type who are more likely to exhibit measurable cognitive decline during the study," the authors write.

Barbara J. Snider, M.D., Ph.D., and colleagues at Washington University School of Medicine, St. Louis, studied 49 individuals with a diagnosis of very mild dementia of the Alzheimer type. Participants underwent a lumbar puncture to obtain a sample of cerebrospinal fluid, which was tested for several biomarkers associated with Alzheimer's disease, including alpha-beta peptide 1-42 (Aβ42), tau and phosphorylated tau 181 (ptau 181). All the participants had at least one follow-up assessment an average of 3.5 years later.

"The rate of dementia progression was significantly more rapid in individuals with lower baseline cerebrospinal fluid Aβ42 levels, higher tau or ptau 181 levels or high tau: Aβ42 ratios," the authors write.

"Although the number of participants in this study was relatively small, the results suggest that CSF biomarkers might be useful as entry criteria for clinical trials of disease-modifying therapies for mild cognitive impairment and very mild dementia of the Alzheimer type," they continue. "Limiting enrollment to individuals with CSF Aβ42 values below a certain cutoff point might ameliorate the difficulties caused by lack of disease progression in some individuals during the trial." For instance, if dementia progresses slowly among all patients in a trial, a larger number of participants would be needed to determine if the treatment was effective over a given time period.

"These findings are likely to have important implications for reducing the number of participants needed to show an effect in clinical trials for very mild dementia of the Alzheimer type and mild cognitive impairment and, ultimately, to assist in making treatment decisions as more invasive and potentially harmful disease-modifying treatments for Alzheimer's disease become available," they conclude.

This study was supported by grants from the National Institutes of Health and by the Charles and Joanne Knight Alzheimer Research Initiative of the WU-ADRC.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Snider et al. Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type. Archives of Neurology, 2009; 66 (5): 638 DOI: 10.1001/archneurol.2009.55

Cite This Page:

JAMA and Archives Journals. "Compounds In Spinal Fluid Associated With Faster Decline Among Individuals With Mild Dementia." ScienceDaily. ScienceDaily, 15 May 2009. <www.sciencedaily.com/releases/2009/05/090511164557.htm>.
JAMA and Archives Journals. (2009, May 15). Compounds In Spinal Fluid Associated With Faster Decline Among Individuals With Mild Dementia. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2009/05/090511164557.htm
JAMA and Archives Journals. "Compounds In Spinal Fluid Associated With Faster Decline Among Individuals With Mild Dementia." ScienceDaily. www.sciencedaily.com/releases/2009/05/090511164557.htm (accessed July 25, 2014).

Share This




More Mind & Brain News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com
Idaho Boy Helps Brother With Disabilities Complete Triathlon

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Newsy (July 23, 2014) An 8-year-old boy helped his younger brother, who has a rare genetic condition that's confined him to a wheelchair, finish a triathlon. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins